World's Best Scientists 2026 revealed!
Giuliano Rizzardini

Giuliano Rizzardini

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Microbiology 48 4639 4268 151 146 310 11980

Giuliano Rizzardini publications per year

The chart shows the history of publications by Giuliano Rizzardini between 1988 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Giuliano Rizzardini published across 38 years, from 1988 to 2025, averaging 10.5 papers a year. Output peaked at 37 publications in 2017. 25 of the 400 publications appeared in the last two years.

No. of publications
10 20 30
Bar chart. Horizontal axis: year, 1988 to 2025. Vertical axis: number of publications, 0 to 37. Peak 37 publications in 2017. 1988: 3 publications 1989: 3 publications 1990: 4 publications 1991: 5 publications 1992: 2 publications 1993: 2 publications 1994: 4 publications 1995: 0 publications 1996: 6 publications 1997: 0 publications 1998: 4 publications 1999: 4 publications 2000: 4 publications 2001: 8 publications 2002: 3 publications 2003: 1 publication 2004: 1 publication 2005: 2 publications 2006: 7 publications 2007: 2 publications 2008: 6 publications 2009: 9 publications 2010: 12 publications 2011: 14 publications 2012: 16 publications 2013: 16 publications 2014: 21 publications 2015: 14 publications 2016: 21 publications 2017: 37 publications 2018: 21 publications 2019: 25 publications 2020: 32 publications 2021: 20 publications 2022: 31 publications 2023: 15 publications 2024: 21 publications 2025: 4 publications
1988 2025

400 publications in total across all disciplines

View publications per year as a table
Giuliano Rizzardini: publications per year, 1988 to 2025
Year Publications
1988 3
1989 3
1990 4
1991 5
1992 2
1993 2
1994 4
1995 0
1996 6
1997 0
1998 4
1999 4
2000 4
2001 8
2002 3
2003 1
2004 1
2005 2
2006 7
2007 2
2008 6
2009 9
2010 12
2011 14
2012 16
2013 16
2014 21
2015 14
2016 21
2017 37
2018 21
2019 25
2020 32
2021 20
2022 31
2023 15
2024 21
2025 4
Total 400
Download as CSV

Giuliano Rizzardini publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Giuliano Rizzardini sits on this spectrum.

No. of scientists
50 100 150 200 250
Bar chart with 64 bars. Horizontal axis: publications, 55–64 to 679+. Vertical axis: number of scientists, 0 to 288. Most scientists, 288, have 135–144 publications. The last bar groups every scientist with 679 publications or more. The highlighted bar, 305–314 publications, is where this scientist sits. 55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 265 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 234 scientists 205–214 publications: 208 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55–64 publications 679+

This scientist: 310 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

View publications distribution as a table
Number of Microbiology scientists by publication count, Research.com 2026 ranking edition. Based on 5,513 ranked scientists.
Publications Scientists This scientist
55–64 8
65–74 29
75–84 55
85–94 112
95–104 137
105–114 190
115–124 235
125–134 234
135–144 288
145–154 265
155–164 264
165–174 253
175–184 276
185–194 190
195–204 234
205–214 208
215–224 198
225–234 155
235–244 161
245–254 160
255–264 146
265–274 139
275–284 148
285–294 115
295–304 96
305–314 88 310
315–324 106
325–334 65
335–344 76
345–354 64
355–364 62
365–374 65
375–384 61
385–394 34
395–404 44
405–414 36
415–424 35
425–434 29
435–444 33
445–454 34
455–464 25
465–474 26
475–484 20
485–494 19
495–504 16
505–514 17
515–524 23
525–534 14
535–544 14
545–554 18
555–564 12
565–574 7
575–584 9
585–594 9
595–604 9
605–614 7
615–624 9
625–634 7
635–644 4
645–654 5
655–664 6
665–674 7
675–678 3
679+ 99
Download as CSV

Giuliano Rizzardini D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Giuliano Rizzardini sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 88 bars. Horizontal axis: D-Index, 40 to 127+. Vertical axis: number of scientists, 0 to 162. Most scientists, 162, have 58 D-Index. The last bar groups every scientist with 127 D-Index or more. The highlighted bar, 48 D-Index, is where this scientist sits. 40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 112 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 123 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 94 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 48 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

View D-Index distribution as a table
Number of Microbiology scientists by D-index, Research.com 2026 ranking edition. Based on 5,513 ranked scientists.
D-Index Scientists This scientist
40 30
41 86
42 90
43 117
44 122
45 123
46 108
47 110
48 106 48
49 109
50 129
51 111
52 116
53 127
54 134
55 134
56 112
57 136
58 162
59 151
60 139
61 123
62 126
63 144
64 109
65 103
66 124
67 112
68 103
69 131
70 94
71 93
72 96
73 92
74 80
75 66
76 87
77 60
78 73
79 59
80 57
81 55
82 47
83 77
84 50
85 45
86 42
87 41
88 32
89 38
90 35
91 34
92 27
93 26
94 33
95 22
96 37
97 22
98 21
99 22
100 30
101 16
102 20
103 17
104 19
105 16
106 19
107 18
108 14
109 10
110 9
111 7
112 11
113 6
114 15
115 10
116 12
117 7
118 10
119 10
120 11
121 2
122 7
123 12
124 5
125 9
126 6
127+ 95
Download as CSV

Overview

Giuliano Rizzardini is affiliated with ASST Fatebenefratelli Sacco in Italy and has contributed extensively to medical research with a focus on infectious diseases. Their work covers a broad range of topics primarily within medicine, with significant efforts in infectious diseases, epidemiology, virology, hepatology, and molecular biology.

Their research frequently appears in journals such as Clinical Infectious Diseases, Journal of Medical Virology, Digestive and Liver Disease, Journal of Hepatology, and Journal of Infection. These venues reflect the core interests of their publications in infectious and liver diseases.

Among the main topics of Giuliano Rizzardini's research are:

  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • HIV/AIDS drug development and treatment
  • Hepatitis C virus research
  • HIV Research and Treatment
  • Poxvirus research and outbreaks
  • COVID-19 and healthcare impacts

Frequent co-authors in their work include Spinello Antinori, Andrea Giacomelli, Massimo Galli, Anna Lisa Ridolfo, and Maria Vittoria Cossu. Collaboration with these colleagues has resulted in numerous publications and contributed to a concentrated expertise in their research fields.

Significant papers authored by or involving Giuliano Rizzardini include:

  • "Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study," 2020, Clinical Infectious Diseases
  • "Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression," 2020, New England Journal of Medicine
  • "COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?" 2020, Clinical and Experimental Rheumatology
  • "Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study," 2020, The Lancet
  • "30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study," 2020, Pharmacological Research

The combination of diverse expertise areas and broad publication record highlights Giuliano Rizzardini's involvement in addressing clinical challenges related to viral infections, particularly in the context of COVID-19 and HIV. Their work reflects an integration of clinical research, epidemiology, and therapeutic development, which contributes to the understanding and management of infectious diseases globally.

Best Publications

  • Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel

    Huldrych F Gunthard;Judith A Aberg;Joseph J Eron;Jennifer Frances Hoy

  • ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

    Peter Ferenci;David Bernstein;Jacob Lalezari;Daniel Cohen

  • COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?

    Piercarlo Sarzi-Puttini;Valeria Giorgi;Silvia Sirotti;Daniela Marotto

  • Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

    Susan Swindells;Jaime-Federico Andrade-Villanueva;Gary J. Richmond;Giuliano Rizzardini

  • Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study

    Hans-Jürgen Stellbrink;Chloe Orkin;Jose Ramon Arribas;Juliet Compston

  • Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    Unknown

  • Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

    Edgar T Overton;Gary Richmond;Giuliano Rizzardini;Hans Jaeger

  • Early Impairment of Gut Function and Gut Flora Supporting a Role for Alteration of Gastrointestinal Mucosa in Human Immunodeficiency Virus Pathogenesis

    Andrea Gori;Andrea Gori;Camilla Tincati;Giuliano Rizzardini;Carlo Torti

  • Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12® and Lactobacillus paracasei ssp. paracasei, L. casei 431® in an influenza vaccination model: a randomised, double-blind, placebo-controlled study.

    Giuliano Rizzardini;Dorte Eskesen;Philip C. Calder;Amedeo Capetti

  • Retinal findings in patients with COVID-19: Results from the SERPICO-19 study.

    Alessandro Invernizzi;Alessandro Invernizzi;Alessandro Torre;Salvatore Parrulli;Federico Zicarelli

  • Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non–AIDS-Defining Events in a Large Cohort of HIV-Infected Patients

    Miriam Lichtner;Paola Cicconi;Serena Vita;Alessandro Cozzi-Lepri

  • Treatment of periodontal disease results in improvements in endothelial dysfunction and reduction of the carotid intima-media thickness

    Stefania Piconi;Daria Trabattoni;Cristina Luraghi;Edoardo Perilli

  • Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial

    A. Gori;G. Rizzardini;B. van't Land;K. B. Amor

  • Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders.

    Stefania Piconi;Serena Parisotto;Giuliano Rizzardini;Simone Passerini

  • AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy

    Nicolas Mounier;Michele Spina;Jean Gabarre;Martine Raphael

  • Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy.

    Stefania Piconi;Daria Trabattoni;Andrea Gori;Serena Parisotto

  • Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.

    Valentina Morena;Laura Milazzo;Letizia Oreni;Giovanna Bestetti

  • Probiotics reduce gut microbial translocation and improve adult atopic dermatitis.

    Enrico Iemoli;Daria Trabattoni;Serena Parisotto;Linda Borgonovo

  • Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

    Alessandro Cozzi-Lepri;Marc Noguera-Julian;Francesca Di Giallonardo;Rob Schuurman

  • Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.

    Matteo Bassetti;Nadia Castaldo;Annamaria Cattelan;Cristina Mussini

  • Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results

    Joel E. Gallant;Ellen Koenig;Jaime Andrade-Villanueva;Ploenchan Chetchotisakd

  • Genomic characterization and phylogenetic analysis of SARS-COV-2 in Italy.

    Gianguglielmo Zehender;Alessia Lai;Annalisa Bergna;Luca Meroni

  • Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections.

    Dario Cattaneo;Giovanna Orlando;Valeria Cozzi;Laura Cordier

Frequent Co-Authors

Massimo Galli
Massimo Galli University of Milan
Carlo Federico Perno
Carlo Federico Perno University of Milan
Mario Clerici
Mario Clerici University of Milan
Antonella d'Arminio Monforte
Antonella d'Arminio Monforte University of Milan
Andrea Antinori
Andrea Antinori Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
Massimo Andreoni
Massimo Andreoni University of Rome Tor Vergata
Andrea Gori
Andrea Gori University of Milan
Massimo Puoti
Massimo Puoti University of Milano-Bicocca
Adriano Lazzarin
Adriano Lazzarin Vita-Salute San Raffaele University
Spinello Antinori
Spinello Antinori University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Microbiology in the USA opens doors to various related career pathways, especially in health and medical fields. For those interested in patient-centered roles, becoming a functional medicine nurse practitioner offers a unique blend of microbiology knowledge and holistic patient care, emphasizing personalized treatment plans.

On the administrative side, the healthcare industry demands expertise in managing health data efficiently. Professionals can explore a certification as a certified professional coder certification to accurately translate healthcare services into standardized codes, a critical skill for billing and compliance.

Those aiming for leadership or organizational roles should consider the evolving field of health information management. Entry-level opportunities often depend on the right qualifications, so checking out the health information management salary entry-level outlook provides useful insight into job expectations and compensation.

Many students prefer flexible learning paths, and enrolling in an online cahiim accredited health information management degree program ensures a credible education that meets industry standards while balancing other commitments.

Best Scientists Citing Giuliano Rizzardini

Trending Scientists

Recently Published Articles